Regeneron Pharmaceuticals announced on Monday that it has extended a long-standing agreement with the United States government to provide an additional supply of its Ebola treatment. The move comes as health officials monitor an escalating outbreak in Africa that has achieved the widest geographic reach of any such event recorded on the continent.
The new agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) serves as an expansion of a contract first established in 2020. Under the terms of the extension, Regeneron is scheduled to supply doses of its drug, Inmazeb, through the year 2031. The value of this supply agreement is estimated at approximately $270 million.
Inmazeb received approval from the U.S. Food and Drug Administration in 2020 for the treatment of infections specifically caused by the Zaire ebolavirus. While Inmazeb remains a critical tool in the global medical arsenal against the disease, the current crisis in Africa presents a different challenge. Health officials confirmed that the ongoing outbreak is caused by the Bundibugyo strain of the virus. Currently, there is no licensed vaccine or approved specific antiviral treatment available for the Bundibugyo strain.
Addressing this gap in medical coverage, Regeneron stated that it is currently testing an experimental therapy known as maftivimab. Researchers are investigating whether the drug can serve as an effective treatment for those infected with the Bundibugyo virus.
The current outbreak was first detected in the Democratic Republic of Congo (DRC) in May. Since its emergence, the virus has spread to four countries across East, Central, and West Africa. The scale of the crisis is significant; in the DRC alone, nearly 10,000 people have been infected, and the death toll has exceeded 4,800. The disease remains a severe threat to public health, typically manifesting as fever, vomiting, and diarrhea. In the most severe cases, patients suffer from internal and external bleeding.
The extended agreement ensures that the U.S. maintains a robust stockpile of Zaire-specific treatments while pharmaceutical developers work to address the shifting needs presented by the Bundibugyo strain. The multi-year commitment highlights the ongoing role of public-private partnerships in preparing for infectious disease emergencies that threaten global health security.
